Related references
Note: Only part of the references are listed.Blockade or deficiency of PD-L1 expression in intestinal allograft accelerates graft tissue injury in mice
Hajime Matsushima et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2022)
Nivolumab for recurrent/metastatic hypopharyngeal squamous cell carcinoma in a liver transplant recipient
Takahito Kondo et al.
AURIS NASUS LARYNX (2022)
Preliminary Evaluation of Atezolizumab plus Bevacizumab as Salvage Treatment for Recurrent Hepatocellular Carcinoma After Liver Transplantation
Zhe Yang et al.
LIVER TRANSPLANTATION (2022)
Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways
Lukas Kraehenbuehl et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2022)
Immune Checkpoint Inhibitors in Transplantation-A Case Series and Comprehensive Review of Current Knowledge
Julie Delyon et al.
TRANSPLANTATION (2021)
Graft Programmed Death Ligand 1 Expression as a Marker for Transplant Rejection Following Anti-Programmed Death 1 Immunotherapy for Recurrent Liver Tumors
Guo-Ming Shi et al.
LIVER TRANSPLANTATION (2021)
Single-cell landscape of the ecosystem in early-relapse hepatocellular carcinoma
Yunfan Sun et al.
CELL (2021)
Hepatocellular carcinoma
Josep M. Llovet et al.
NATURE REVIEWS DISEASE PRIMERS (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Extending the Use of Atezolizumab and Bevacizumab to a Liver Transplant Recipient: Need for a Posttransplant Registry
Najib Ben Khaled et al.
LIVER TRANSPLANTATION (2021)
CTLA-4 blockade drives loss of Treg stability in glycolysis-low tumours
Roberta Zappasodi et al.
NATURE (2021)
Improvement of PD-1 Blockade Efficacy and Elimination of Immune-Related Gastrointestinal Adverse Effect by mTOR Inhibitor
Xin Bai et al.
FRONTIERS IN IMMUNOLOGY (2021)
Advances in immunotherapy for hepatocellular carcinoma
Bruno Sangro et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2021)
High trough levels of everolimus combined to sorafenib improve patients survival after hepatocellular carcinoma recurrence in liver transplant recipients
Hidetoshi Nitta et al.
TRANSPLANT INTERNATIONAL (2021)
Effect of Mycophenolate Mofetil Therapy on Recurrence of Hepatocellular Carcinoma after Liver Transplantation: A Population-Based Cohort Study
Yung-Fong Tsai et al.
JOURNAL OF CLINICAL MEDICINE (2021)
The Outcomes of Systemic Treatment in Recurrent Hepatocellular Carcinomas Following Liver Transplants
Bryan Cho Wing Li et al.
ADVANCES IN THERAPY (2021)
Endothelial Stromal PD-L1 (Programmed Death Ligand 1) Modulates CD8+ T-Cell Infiltration After Heart Transplantation
William Bracamonte-Baran et al.
CIRCULATION-HEART FAILURE (2021)
Efficacy and Safety of Lenvatinib in Hepatocellular Carcinoma Patients with Liver Transplantation: A Case-Control Study
Yen-Yang Chen et al.
CANCERS (2021)
Therapeutic Efficacy of Sorafenib in Patients with Hepatocellular Carcinoma Recurrence After Liver Transplantation: A Systematic Review and Meta-Analysis
Zhao Li et al.
TURKISH JOURNAL OF GASTROENTEROLOGY (2021)
Immune checkpoint inhibitor for hepatocellular carcinoma recurrence after liver transplantation
Li Zhuang et al.
HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL (2020)
Anti-PD-1 antibody decreases tumour-infiltrating regulatory T cells
Kazushige Yoshida et al.
BMC CANCER (2020)
Acute rejection after liver transplantation is less common, but predicts better prognosis in HBV-related hepatocellular carcinoma patients
Jia-Xi Mao et al.
HEPATOLOGY INTERNATIONAL (2020)
Immune Checkpoint Inhibitors in Patients with Recurrent Hepatocellular Carcinoma after Liver Transplantation: A Case Report and Literature Review
Jianguo Qiu et al.
CURRENT CANCER DRUG TARGETS (2020)
Ipilumumab for hepatocellular cancer in a liver transplant recipient, with durable response, tolerance and without allograft rejection
Abhishek Pandey et al.
IMMUNOTHERAPY (2020)
mTOR Inhibition Is Most Beneficial After Liver Transplantation for Hepatocellular Carcinoma in Patients With Active Tumors
Andreas A. Schnitzbauer et al.
ANNALS OF SURGERY (2020)
Immunosuppression in liver transplant
Tommaso Di Maira et al.
BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY (2020)
Understanding, predicting and achieving liver transplant tolerance: from bench to bedside
Angus W. Thomson et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2020)
Liver Transplantation for Hepatocellular Carcinoma. Working Group Report from the ILTS Transplant Oncology Consensus Conference
Neil Mehta et al.
TRANSPLANTATION (2020)
Nivolumab Induced Hepatocanalicular Cholestasis and Liver Rejection in a Patient With Lung Cancer and Liver Transplant
Marius Braun et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
PD-L1 on dendritic cells attenuates T cell activation and regulates response to immune checkpoint blockade
Qi Peng et al.
NATURE COMMUNICATIONS (2020)
PD-L1 Reverse Signaling in Dermal Dendritic Cells Promotes Dendritic Cell Migration Required for Skin Immunity
Erin D. Lucas et al.
CELL REPORTS (2020)
Revisiting the PD-1 pathway
Nikolaos Patsoukis et al.
SCIENCE ADVANCES (2020)
Anti-Programmed Cell Death Protein 1 (PD-1) Immunotherapy for Metastatic Hepatocellular Carcinoma After Liver Transplantation: A Report of Three Cases
Ouissam Al Jarroudi et al.
CUREUS JOURNAL OF MEDICAL SCIENCE (2020)
Successful Treatment of Disseminated Hepatocellular Carcinoma After Liver Transplantation With Nivolumab
Waseem Amjad et al.
JOURNAL OF CLINICAL AND EXPERIMENTAL HEPATOLOGY (2020)
Regulatory T cells in solid organ transplantation
Muhammad Atif et al.
CLINICAL & TRANSLATIONAL IMMUNOLOGY (2020)
PD-1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer
Takahiro Kamada et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials A Systematic Review and Meta-analysis
Yucai Wang et al.
JAMA ONCOLOGY (2019)
PD-1 Blockade in a Liver Transplant Recipient With Microsatellite Unstable Metestatic Colorectal Cancer and Hepatic Impairment
Justin A. Chen et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2019)
A global view of hepatocellular carcinoma: trends, risk, prevention and management
Ju Dong Yang et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2019)
Nivolumab-Induced Severe Allograft Rejection in Recurrent Post-Transplant Hepatocellular Carcinoma
Shiva Kumar
AMERICAN JOURNAL OF GASTROENTEROLOGY (2019)
Liver graft rejection following immune checkpoint inhibitors treatment: a review
Bo Hu et al.
MEDICAL ONCOLOGY (2019)
Targeting the mTOR pathway uncouples the efficacy and toxicity of PD-1 blockade in renal transplantation
Khashayar Esfahani et al.
NATURE COMMUNICATIONS (2019)
CD8+ cytotoxic T lymphocytes in cancer immunotherapy: A review
Bagher Farhood et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2019)
Pembrolizumab for metastatic hepatocellular carcinoma following live donor liver transplantation: The silver bullet?
Ashwin Rammohan et al.
HEPATOLOGY (2018)
Graft-infiltrating PD-L1hi cross-dressed dendritic cells regulate antidonor T cell responses in mouse liver transplant tolerance
Yoshihiro Ono et al.
HEPATOLOGY (2018)
Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression
Heng Lin et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Immune checkpoint inhibitor therapy in a liver transplant recipient with a rare subtype of melanoma: a case report and literature review
James C. Kuo et al.
MELANOMA RESEARCH (2018)
Role of PD-1 during effector CD8 T cell differentiation
Eunseon Ahn et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Cancer immunotherapy using checkpoint blockade
Antoni Ribas et al.
SCIENCE (2018)
Programmed Cell Death Ligand 1 (PD-L1) Signaling Regulates Macrophage Proliferation and Activation
Genevieve P. Hartley et al.
CANCER IMMUNOLOGY RESEARCH (2018)
Use of checkpoint inhibitors in liver transplant recipients
Stefan Munker et al.
UNITED EUROPEAN GASTROENTEROLOGY JOURNAL (2018)
Targeting LAG-3 and PD-1 to Enhance T Cell Activation by Antigen-Presenting Cells
Felix S. Lichtenegger et al.
FRONTIERS IN IMMUNOLOGY (2018)
mTOR signalling and cellular metabolism are mutual determinants in cancer
Dirk Mossmann et al.
NATURE REVIEWS CANCER (2018)
Liver Allograft Failure After Nivolumab Treatment-A Case Report With Systematic Literature Research
Dimitri Gassmann et al.
TRANSPLANTATION DIRECT (2018)
PD-1 expression on CD8+ T cells regulates their differentiation within lung allografts and is critical for tolerance induction
T. Takahashi et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2018)
Macrophage subpopulations and their impact on chronic allograft rejection versus graft acceptance in a mouse heart transplant model
Yue Zhao et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2018)
Safety of an anti-PD-1 immune checkpoint inhibitor in a liver transplant recipient
P. Biondani et al.
ANNALS OF ONCOLOGY (2018)
Pilot evaluation of PD-1 inhibition in metastatic cancer patients with a history of liver transplantation: the Mayo Clinic experience
Thomas T. DeLeon et al.
JOURNAL OF GASTROINTESTINAL ONCOLOGY (2018)
Impact of Immunosuppressive Drugs on the Metabolism of T Cells
Nicolas Pallet et al.
BIOLOGY OF T CELLS, PT A (2018)
Tapering of Immunosuppression and Sustained Treatment With Nivolumab in a Liver Transplant Recipient
Enrico N. De Toni et al.
GASTROENTEROLOGY (2017)
Recurrence of hepatocellular carcinoma after liver transplantation: Is there a place for resection?
Elena Fernandez-Sevilla et al.
LIVER TRANSPLANTATION (2017)
PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity
Sydney R. Gordon et al.
NATURE (2017)
Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches
Gonzalo Sapisochin et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2017)
Fatal orthotopic liver transplant organ rejection induced by a checkpoint inhibitor in two patients with refractory, metastatic hepatocellular carcinoma
Brian D. Friend et al.
PEDIATRIC BLOOD & CANCER (2017)
The induction and Maintenance of Transplant Tolerance engages Both regulatory and anergic CD4+ T cells
Alix Besancon et al.
FRONTIERS IN IMMUNOLOGY (2017)
Preserved Liver Transplant After PD-1 Pathway Inhibitor for Hepatocellular Carcinoma
Andreas Varkaris et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2017)
A national report from China Liver Transplant Registry: steroid avoidance after liver transplantation for hepatocellular carcinoma
Qiang Wei et al.
CHINESE JOURNAL OF CANCER RESEARCH (2017)
Acute liver graft rejection after ipilimumab therapy
S. Dueland et al.
ANNALS OF ONCOLOGY (2017)
Immune Checkpoint Inhibitor Therapy in a Liver Transplant Recipient With Melanoma
Gustavo Schvartsman et al.
ANNALS OF INTERNAL MEDICINE (2017)
Efficacy and Safety of Everolimus and Mycophenolic Acid With Early Tacrolimus Withdrawal After Liver Transplantation: A Multicenter Randomized Trial
F. Saliba et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2017)
Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation
Ana C. Anderson et al.
IMMUNITY (2016)
Is radiofrequency ablation applicable for recurrent hepatocellular carcinoma after liver transplantation?
Jiwei Huang et al.
JOURNAL OF SURGICAL RESEARCH (2016)
Phosphatase PP2A is requisite for the function of regulatory T cells
Sokratis A. Apostolidis et al.
NATURE IMMUNOLOGY (2016)
Tumor Regression and Allograft Rejection after Administration of Anti-PD-1
Evan J. Lipson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial
Edward K. Geissler et al.
TRANSPLANTATION (2016)
TGFβ-dependent expression of PD-1 and PD-L1 controls CD8+ T cell anergy in transplant tolerance
Marije Baas et al.
ELIFE (2016)
Evolving Perspectives of mTOR Complexes in Immunity and Transplantation
D. Fantus et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2015)
Deletion of CTLA-4 on regulatory T cells during adulthood leads to resistance to autoimmunity
Alison M. Paterson et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2015)
Administration of Ipilimumab to a Liver Transplant Recipient With Unresectable Metastatic Melanoma
Harsha A. Ranganath et al.
JOURNAL OF IMMUNOTHERAPY (2015)
Safety and efficacy of ipilimumab to treat advanced melanoma in the setting of liver transplantation
Rita E. Morales et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2015)
Liver transplantation: immunosuppression and oncology
Manuel Rodriguez-Peralvarez et al.
CURRENT OPINION IN ORGAN TRANSPLANTATION (2014)
Comparative efficacy of sorafenib versus best supportive care in recurrent hepatocellular carcinoma after liver transplantation: A case-control study
Carlo Sposito et al.
JOURNAL OF HEPATOLOGY (2013)
Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma
Manuel Rodriguez-Peralvarez et al.
JOURNAL OF HEPATOLOGY (2013)
Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells
Mark J. Selby et al.
CANCER IMMUNOLOGY RESEARCH (2013)
PD-1/B7-H1 Interaction Contribute to the Spontaneous Acceptance of Mouse Liver Allograft
M. Morita et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2010)
Effect of Different Immunosuppressive Schedules on Recurrence-Free Survival After Liver Transplantation for Hepatocellular Carcinoma
Marco Vivarelli et al.
TRANSPLANTATION (2010)
Liver Transplantation for Hepatocellular Carcinoma Under Calcineurin Inhibitors Reassessment of Risk Factors for Tumor Recurrence
Marco Vivarelli et al.
ANNALS OF SURGERY (2008)
被撤回的出版物: Liver transplantation for hepatocellular carcinoma: Hangzhou experiences (Retracted article. See vol. 103, pg. 1736, 2019)
Shu-Sen Zheng et al.
TRANSPLANTATION (2008)
Tumor response to transcatheter arterial chemoembolization in recurrent hepatocellular carcinoma after living donor liver transplantation
Heung-Kyu Ko et al.
KOREAN JOURNAL OF RADIOLOGY (2007)
Tacrolimus enhances transforming growth factor-β1 expression and promotes tumor progression
M Maluccio et al.
TRANSPLANTATION (2003)
Liver transplantation for hepatocellular carcinoma: Expansion of the tumor size limits does not adversely impact survival
FY Yao et al.
HEPATOLOGY (2001)
Share Paper
